J Korean Med Sci.  2014 May;29(5):657-661. 10.3346/jkms.2014.29.5.657.

Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy

• Joo K
• Kwon SR
• Lim MJ
• Jung KH
• Joo H
• Park W

• KMID: 1786106
• DOI: http://doi.org/10.3346/jkms.2014.29.5.657

Abstract

The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients. We retrospectively reviewed patients who were diagnosed to have gout with at least 3 yr of follow up. They were divided into 2 groups; 53 patients with mean serum uric acid level (sUA)<6 mg/dL and 147 patients with mean sUA> or =6 mg/dL. Comorbidities of gout such as hypertension (HTN), type II diabetes mellitus (DM), chronic kidney disease, cardiovascular disease (CVD) and urolithiasis were compared in each group at baseline and at last follow-up visit. Frequency of acute gout attacks were also compared between the groups. During the mean follow up period of 7.6 yr, the yearly rate of acute attack and the new development of HTN, DM, CVD and urolithiasis was lower in the adequately treated group compared to the inadequately treated group. Tight control of uric acid decreases the incidence of acute gout attacks and comorbidities of gout such as HTN, DM, CVD and urolithiasis.

Keyword

Gout; Hypertension; Diabetes Mellitus; Cardiovascular Diseases; Urolithiasis; Renal Insufficiency; Comorbidity; Allopurinol

MeSH Terms

Adult
Allopurinol/therapeutic use
Antimetabolites/therapeutic use
Benzbromarone/therapeutic use
Cardiovascular Diseases/epidemiology/prevention & control
Comorbidity
Diabetes Mellitus, Type 2/epidemiology/prevention & control
Enzyme Inhibitors/therapeutic use
Female
Gout/*drug therapy/*prevention & control
Gout Suppressants/*therapeutic use
Humans
Hypertension/epidemiology/prevention & control
Male
Middle Aged
Renal Insufficiency, Chronic/epidemiology/prevention & control
Retrospective Studies
Thiazoles/therapeutic use
Uric Acid/*blood/metabolism
Uricosuric Agents/therapeutic use
Urolithiasis/epidemiology/prevention & control
Allopurinol
Antimetabolites
Benzbromarone
Enzyme Inhibitors
Gout Suppressants
Thiazoles
Uric Acid
Uricosuric Agents

Reference

1. Tarng DC, Lin HY, Shyong ML, Wang JS, Yang WC, Huang TP. Renal function in gout patients. Am J Nephrol. 1995; 15:31–37.

2. Smith EU, Díaz-Torné C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010; 24:811–827.

3. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011; 63:3136–3141.

4. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004; 51:321–325.

5. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford). 2013; 52:34–44.

6. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, et al. 2012 American College of Rheumatology guidelines for management of gout: part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64:1431–1446.

7. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977; 20:895–900.

8. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004; 31:1575–1581.

9. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006; 81:925–934.

10. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008; 67:609–613.

11. Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, Chen L, Dalbeth N, Sivera F, Vázquez-Mellado J, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 2012; 64:1508–1517.

12. Schlesinger N, Schumacher HR Jr. Gout: can management be improved? Curr Opin Rheumatol. 2001; 13:240–244.

13. Beutler AM, Rull M, Schlesinger N, Baker DG, Hoffman BI, Schumacher HR Jr. Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels. Clin Exp Rheumatol. 2001; 19:595.

14. Emmerson BT. The management of gout. N Engl J Med. 1996; 334:445–451.

15. Sivera F, Andrés M, Carmona L, Kydd AS, Moi J, Seth R, Sriranganathan M, van Durme C, van Echteld I, Vinik O, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014; 73:328–335.

16. Edwards NL. Management of hyperuricemia. In : Koopman WJ, editor. Arthritis and allied conditions. 14th ed. Philadelphia: Lippincott Williams & Wilkins;2001. p. 2314–2328.

17. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008; 67:960–966.

18. Chen SY, Chen CL, Shen ML. Manifestations of metabolic syndrome associated with male gout in different age strata. Clin Rheumatol. 2007; 26:1453–1457.

19. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007; 39:1227–1233.

20. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008; 300:924–932.

21. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels: the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford). 2008; 47:713–717.

22. Niskanen L, Laaksonen DE, Lindström J, Eriksson JG, Keinänen-Kiukaanniemi S, Ilanne-Parikka P, Aunola S, Hämäläinen H, Tuomilehto J, Uusitupa M. Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care. 2006; 29:709–711.

23. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008; 47:1567–1570.

24. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003; 41:1287–1293.

25. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988; 41:237–242.

26. Edwards N. The role of hyperuricaemia in vascular disorders. Curr Opin Rheumatol. 2009; 21:132–137.

27. Rentoukas E, Tsarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, Vavetsi S. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010; 145:257–258.

28. Scott R. Epidemiology of stone disease. Br J Urol. 1985; 57:491–497.

29. Yü T, Gutman AB. Uric acid nephrolithiasis in gout: predisposing factors. Ann Intern Med. 1967; 67:1133–1148.

30. Shimizu T, Kitada H, Umeyama M, Hori H, Takasaki N. Novel evaluation of nephrolithiasis as a complication of gout: a cross-sectional study using helical computerized tomography. J Urol. 2013; 189:1747–1752.

31. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012; 125:679–687.e1.

32. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008; 28:437–443.

33. Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011; 78:456–459.